At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 577 enrolled
Drug / intervention
Erenumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
In Brief
A Phase 3 clinical trial evaluating Erenumab and Placebo for Migraine. Completed, enrolled 577 participants across 76 sites in 8 countries.
Detailed Summary
To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesDenmark, France, Greece, Portugal, Russia, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartJul 2015
Primary CompletionJul 2016
Study CompletionMar 2017
TodayJul 2026
First PostedJun 29, 2015
Enrollment StartJul 20, 2015
Primary CompletionJul 11, 2016
Study CompletionMar 20, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 11.0 years ago
Interventions
Erenumabdrug
Administered once a month by subcutaneous injection
Placebodrug
Administered once a month by subcutaneous injection